Short-course aminoglycosides as adjunctive treatment in adults with sepsis

Withdrawn

• Conditions: infection; Sepsis; 10004018

• Registration Number: NL-OMON50795
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 3140

Inclusion Criteria

1) Age ><= 18 years
2) Presenting to the ER
3) Suspicion of bacterial infection of unknown origin, primary suspected
urinary origin or primary suspected abdominal origin.
4) National Early Warning Score (NEWS) or Modified Early Warning Score (MEWS) *
5.
5) Requiring intravenous antibiotic treatment and hospitalization.

Exclusion Criteria

1) Working diagnosis at the ER of pneumonia.
2) Chemotherapy induced neutropenia as this is considered a separate entity in
the guidelines.
3) Pre-existing renal failure defined as a GFR < 30, due to a relative
contra-indication for aminoglycosides.
4) Allergy for cephalosporins or aminoglycosides, known prior to the start of
treatment.
5) Indication for empirical coverage of ESBL-producing gram-negative bacteria
according to the Dutch sepsis guidelines, i.e. known colonization or infection
with ESBL-producing gram-negative bacteria in the prior year.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>30-day all-cause mortality</p><br>